[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-381380-105":59,"doc-detail-381380-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","innate-immunity-in-cancer-biology-and-therapy","Innate Immunity in Cancer Biology and Therapy","","Immunotherapies such as adaptive immune checkpoint inhibitors and CAR T cells have transformed clinical cancer treatment, yet durable benefits remain limited to subsets of patients. Innate immunity is shown to critically shape the tumor microenvironment and affect clinical outcomes. Understanding the innate immune cell populations infiltrating tumors supports the development of new therapeutics. This review summarizes roles and mechanisms, discusses innate immunity-based cancer immunotherapy across basic and clinical research, and addresses challenges in driving effective innate immune responses and strategies to improve antitumor efficacy.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/innate-immunity-in-cancer-biology-and-therapy/381380/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/innate-immunity-in-cancer-biology-and-therapy/381380.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-27","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"What does the review cover regarding innate immunity-based cancer immunotherapy?","Question",{"text":112,"@type":113},"It outlines the roles and mechanisms of innate immunity in the tumor microenvironment and discusses innate immunity-based immunotherapy findings from basic and clinical studies.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},381380,1790367079,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Review  \nInnate Immunity in Cancer Biology and Therapy  \nYuxia Zhang 1, Wenjing Xue 1, Caili Xu 1, Yanyang Nan 1, Shuang Mei 2, Dianwen Ju 1, Shaofei Wang 3, * and Xuyao Zhang 1, *  \nCitation: Zhang, Y.; Xue, W.; Xu, C.; Nan, Y.; Mei, S.; Ju, D.; Wang, S.; Zhang, X. Innate Immunity in Cancer Biology and Therapy. Int. J. Mol. Sci. 2023, 24, 11233. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms241411233](10.3390/ijms241411233)  \nAcademic Editor: Atsushi Matsuzawa  \nReceived: 21 May 2023  \nRevised: 5 July 2023  \nAccepted: 5 July 2023  \nPublished: 8 July 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China; [20301030096@fudan.edu.cn](20301030096@fudan.edu.cn) (Y.Z.); [22211030033@m.fudan.edu.cn](22211030033@m.fudan.edu.cn) (W.X.); [21111030069@m.fudan.edu.cn](21111030069@m.fudan.edu.cn) (C.X.); [20111030070@fudan.edu.cn](20111030070@fudan.edu.cn) (Y.N.); [dianwenju@fudan.edu.cn](dianwenju@fudan.edu.cn) (D.J.)  \n2 Shanghai Tinova Immune Therapeutics Co., Ltd., Shanghai 201413, China; [s.mei@novatim-zj2.com](s.mei@novatim-zj2.com)  \n3 Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China  \n* Correspondence: [shaofeiwang@fudan.edu.cn](shaofeiwang@fudan.edu.cn) (S.W.); [xuyaozhang@fudan.edu.cn](xuyaozhang@fudan.edu.cn) (X.Z.); Tel.: +86-21-54237656 (S.W.); +86-21-51980037 (X.Z.)  \nAbstract: Immunotherapies including adaptive immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells, have developed the treatment of cancer in clinic, and most of them focus on activating T cell immunity. Although these strategies have obtained unprecedented clinical responses, only limited subsets of cancer patients could receive long-term benefits, highlighting the demand for identifying novel targets for the new era of tumor immunotherapy. Innate immunity has been demonstrated to play a determinative role in the tumor microenvironment (TME) and influence the clinical outcomes of tumor patients. A thorough comprehension of the innate immune cells that infiltrate tumors would allow for the development of new therapeutics. In this review, we outline the role and mechanism of innate immunity in TME. Moreover, we discuss innate immunity-based cancer immunotherapy in basic and clinical studies. Finally, we summarize the challenges in sufficiently motivating innate immune responses and the corresponding strategies and measures to improve anti-tumor efficacy. This review could aid the comprehension of innate immunity and inspire the creation of brand-new immunotherapies for the treatment of cancer.  \nKeywords: innate immunity; cancer therapy; immune checkpoint inhibitors; chimeric antigen receptors; cytokines  \n1. Introduction  \nCancer is one of the main leading causes of disease-associated death and it often results from genotoxic and non-genotoxic carcinogens [1] . Surgery, chemotherapy, radiotherapy and tumor immunotherapy are the principle treatment for tumors. Surgery is the treatment of choice for most solid tumors, but cannot be used for hematologic tumors and metastases and subclinical metastases of solid tumors. Compared to surgical treatment, chemotherapy is a systemic treatment for primary, metastatic and subclinical metastases of solid tumors as well as hematologic tumors. However, the poor selectivity of chemotherapeutic agents limits its clinical application. Radiation therapy protects tissue that is not affected by the tumor, produces less damage and does not require hospital","cbCaigzu6fNo6A7C","https://ap.wps.com/l/cbCaigzu6fNo6A7C","pdf",1223872,18,"English","# Introduction\n# Innate Immunity in the Tumor Microenvironment\n## Innate immune cells and tumor development\n## Innate immunity-based cancer immunotherapy\n# Challenges and strategies to enhance innate immune responses\n# Conclusion","[{\"question\":\"What does the review cover regarding innate immunity-based cancer immunotherapy?\",\"answer\":\"It outlines the roles and mechanisms of innate immunity in the tumor microenvironment and discusses innate immunity-based immunotherapy findings from basic and clinical studies.\"}]","Innate Immunity in Cancer Biology and Therapy | PDF",1790245076,45]